ELSEVIER

Journal of Controlled Release 49 (1997) 309–310

journal of controlled release

Author Index Volume 49 (1997)

Acemoglu, M., Nimmerfall, F., Bantle, S. and Stoll, G.H., Poly(ethylene carbonate)s, part I: Syntheses and structural effects on biodegradation (49) 263
Akimoto, T., Aoyagi, T., Minoshima, J.-i. and Nagase, Yu., Polymeric percutaneous drug penetration enhancer. Synthesis and enhancing property of PEG/PDMS block copolymer with a cationic end group (49) 229
Alpar, H.O., see Conway, B.R. (49) 1
Alyautdin, R.N., see Kreuter, J. (49) 81
Aoyagi, T., see Akimoto, T. (49) 229
Auriola, S., see Mari Hämäläinen, K. (49) 97
Banga, A.K., see Katakam, M. (49) 21
Bantle, S., see Acemoglu, M. (49) 263
Bentz, H., see Schroeder-Tefft, J.A. (49) 291
Boltze, L., see Huth, S. (49) 141
Borchardt, R.T., see Okumu, F.W. (49) 133
Boyd, B., see Cleland, J.L. (49) 193
Brooks, D., see Cleland, J.L. (49) 193
Brown, A.F., see Jones, D.S. (49) 71
Celniker, A.C., see Cleland, J.L. (49) 193
Chen, G., see Inoue, T. (49) 167
Cherng, J.-Y., see van de Wetering, P. (49) 59
Cho, C.-S., see Ha, J.-H. (49) 253
Chu, H., see Cleland, J.L. (49) 193
Chung, S.-J., see Hwang, B.-Y. (49) 177
Cleland, J.L., Duenas, E., Daugherty, A., Marian, M., Yang, J., Wilson, M., Celniker, A.C., Shahzamani, A., Quarmby, V., Chu, H., Mukku, V., Mac, A., Roussakis, M., Gillette, N., Boyd, B., Yeung, D., Brooks, D., Maa, Yu.-F., Hsu, C. and Jones, A.J.S., Recombinant human growth hormone poly-(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect (49) 193
Cleland, J.L., see Okumu, F.W. (49) 133
Cole, M.L. and Whateley, T.L., Release rate profiles of theophylline and insulin from stable multiple w/o/w emulsions (49) 51
Conway, B.R., Eyles, J.E. and Alpar, H.O., A comparative study on the immune responses to antigens in PLA and PHB microspheres (49) 1
Daugherty, A., see Cleland, J.L. (49) 193
Duenas, E., see Cleland, J.L. (49) 193
Duizer, E., Penninks, A.H., Stenhuis, W.H. and Groten, J.P., Comparison of permeability characteristics of the human colonic Caco-2 and rat small intestinal IEC-18 cell lines (49) 39
Estridge, T.D., see Schroeder-Tefft, J.A. (49) 291
Eyles, J.E., see Conway, B.R. (49) 1
Fornasini, G., see Steed, K.P. (49) 115
Fouchard, D., Hueber, F., Teillaud, E. and Marty, J.-P., Effects of iontophoretic current flow on hairless rat skin in vivo (49) 89
Gabor, F., Wirth, M., Jurkovich, B., Haberl, I., Theyer, G., Walcher, G. and Hamilton, G., Lectin-mediated bioadhesion: Proteolytic stability and binding-characteristics of *wheat germ* agglutinin and *Solanum tuberosum* lectin on Caco-2, HT-29 and human colonocytes (49) 27
Gillette, N., see Cleland, J.L. (49) 193
Groten, J.P., see Duizer, E. (49) 39
Ha, J.-H., Kim, S.-H., Han, S.-Y., Sung, Y.-K., Lee, Y.-M., Kang, I.-K. and Cho, C.-S., Albumin release from bioerodible hydrogels based on semi-interpenetrating polymer networks composed of poly(ϵ-caprolactone) and poly(ethylene glycol) macromer (49) 253
Haberl, I., see Gabor, F. (49) 27
Hamilton, G., see Gabor, F. (49) 27
Han, S.-Y., see Ha, J.-H. (49) 253
Hennink, W.E., see Van de Wetering, P. (49) 59
Hirano, T., see Šubr, V. (49) 123
Ho, H.-O., Liu, C.-H., Lin, H.-M. and Sheu, M.-T., The development of matrix tablets for diclofenac sodium based on an empirical in vitro and in vivo correlation (49) 149
Ho, H.-O., Wang, H.-Y. and Sheu, M.-T., The evaluation of granulated excipients as matrix material for controlled delivery of captopril (49) 243
Hoffman, A.S., see Inoue, T. (49) 167
Hooper, G., see Steed, K.P. (49) 115
Horikoshi, I., see Wang, Ya M. (49) 157
Hsu, C., see Cleland, J.L. (49) 193
Hueber, F., see Fouchard, D. (49) 89
Huth, S., Boltze, L. and Neubert, R., Mathematical assessment of different penetration mechanisms from vehicles with propylene glycol (49) 141
Hwang, B.-Y., Jung, B.-H., Chung, S.-J., Lee, M.-H. and Shim, C.-K., In vitro skin permeation of nicotine from proliposomes (49) 177
Iga, K. and Ogawa, Y., Sustained-release buccal dosage forms for nitroglycerin and isosorbide dinitrate: increased bioavailability and extended time of absorption when administered to dogs (49) 105
Ikeda, M., see Miyajima, M. (49) 207
Inoue, T., Chen, G., Nakamae, K. and Hoffman, A.S., A hydrophobically-modified bioadhesive polyelectrolyte hydrogel for drug delivery (49) 167

Ito, Y., see Šubr, V. (49) 123
Jones, A.J.S., see Cleland, J.L. (49) 193
Jones, D.S., Woolfson, A.D., Brown, A.F. and O'Neill, M.J., Mucoadhesive, syringeable drug delivery systems for controlled application of metronidazole to the periodontal pocket: In vitro release kinetics, syringeability, mechanical and mucoadhesive properties (49) 71
Jung, B.-H., see Hwang, B.-Y. (49) 177
Jurkovich, B., see Gabor, F. (49) 27
Kang, I.-K., see Ha, J.-H. (49) 253
Katakam, M., Ravis, W.R. and Banga, A.K., Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels (49) 21
Kharkevich, D.A., see Kreuter, J. (49) 81
Kim, S.-H., see Ha, J.-H. (49) 253
Kollias, K., see Maitani, Y. (49) 185
Kontturi, K., see Mari Hämäläinen, K. (49) 97
Koshika, A., see Miyajima, M. (49) 207
Kreuter, J., Petrov, V.E., Kharkevich, D.A. and Alyautdin, R.N., Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles (49) 81
Lee, M.-H., see Hwang, B.-Y. (49) 177
Lee, Y.-M., see Ha, J.-H. (49) 253
Lin, H.-M., see Ho, H.-O. (49) 149
Liu, C.-H., see Ho, H.-O. (49) 149
Maa, Yu.-F., see Cleland, J.L. (49) 193
Mac, A., see Cleland, J.L. (49) 193
Maitani, Y., Nagai, T., Kollias, K. and Peppas, N.A., Design of ocular/lacrimal and nasal systems through analysis of drug administration and absorption (49) 185
Mari Hämäläinen, K., Kontturi, K., Auriola, S., Murtomäki, L. and Urtti, A., Estimation of pore size and pore density of biomembranes from permeability measurements of polyethylene glycols using an effusion-like approach (49) 97
Marian, M., see Cleland, J.L. (49) 193
Marty, J.-P., see Fouchard, D. (49) 89
Minoshima, J.-i., see Akimoto, T. (49) 229
Miyajima, M., Koshika, A., Okada, J., Ikeda, M. and Nishimura, K., Effect of polymer crystallinity on papaverine release from poly (L-lactic acid) matrix (49) 207
Monti, N., see Steed, K.P. (49) 115
Mukku, V., see Cleland, J.L. (49) 193
Murtomäki, L., see Mari Hämäläinen, K. (49) 97
Nagai, T., see Maitani, Y. (49) 185
Nagai, T., see Takahara, J. (49) 11
Nagase, Yu., see Akimoto, T. (49) 229
Nakamae, K., see Inoue, T. (49) 167
Neubert, R., see Huth, S. (49) 141
Nimmerfall, F., see Acemoglu, M. (49) 263
Nishimura, K., see Miyajima, M. (49) 207
Ogawa, Y., see Iga, K. (49) 105
Okada, J., see Miyajima, M. (49) 207
Okumu, F.W., Cleland, J.L. and Borchardt, R.T., The effect of size, charge and cyclization of model peptides on their in vitro release from DL–PLGA microspheres (49) 133
O'Neill, M.J., see Jones, D.S. (49) 71
Penninks, A.H., see Duizer, E. (49) 39
Peppas, N.A., see Maitani, Y. (49) 185
Petrov, V.E., see Kreuter, J. (49) 81
Quarmby, V., see Cleland, J.L. (49) 193
Ravis, W.R., see Katakam, M. (49) 21
Rim Hwang, J. and Sefton, M.V., Effect of capsule diameter on the permeability to horseradish peroxidase of individual HEMA-MMA microcapsules (49) 217
Roussakis, M., see Cleland, J.L. (49) 193
Sato, H., see Wang, Ya M. (49) 157
Schroeder-Tefft, J.A., Bentz, H. and Estridge, T.D., Collagen and heparin matrices for growth factor delivery (49) 291
Sefton, M.V., see Rim Hwang, J. (49) 217
Shahzamani, A., see Cleland, J.L. (49) 193
Sheu, M.-T., see Ho, H.-O. (49) 149
Sheu, M.-T., see Ho, H.-O. (49) 243
Shim, C.-K., see Hwang, B.-Y. (49) 177
Steed, K.P., Hooper, G., Monti, N., Strolin Benedetti, M., Fornasini, G. and Wilding, I.R., The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIME CLOCK®" system) (49) 115
Stenhuis, W.H., see Duizer, E. (49) 39
Stoll, G.H., see Acemoglu, M. (49) 263
Strohalm, J., see Šubr, V. (49) 123
Strolin Benedetti, M., see Steed, K.P. (49) 115
Šubr, V., Strohalm, J., Hirano, T., Ito, Y. and Ulbrich, K., Poly[*N*-(2-hydroxypropyl)methacrylamide] conjugates of methotrexate. Synthesis and in vitro drug release (49) 123
Sung, Y.-K., see Ha, J.-H. (49) 253
Takahara, J., Takayama, K. and Nagai, T., Multi-objective simultaneous optimization technique based on an artificial neural network in sustained release formulations (49) 11
Takayama, K., see Takahara, J. (49) 11
Talsma, H., see Van de Wetering, P. (49) 59
Teillaud, E., see Fouchard, D. (49) 89
Theyer, G., see Gabor, F. (49) 27
Ulbrich, K., see Šubr, V. (49) 123
Urtti, A., see Mari Hämäläinen, K. (49) 97
van de Wetering, P., Cherng, J.-Y., Talsma, H. and Hennink, W.E., Relation between transfection efficiency and cytotoxicity of poly(2-(dimethylamino)ethyl methacrylate)/plasmid complexes (49) 59
Walcher, G., see Gabor, F. (49) 27
Wang, H.-Y., see Ho, H.-O. (49) 243
Wang, Ya M., Sato, H. and Horikoshi, I., In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres (49) 157
Whateley, T.L., see Cole, M.L. (49) 51
Wilding, I.R., see Steed, K.P. (49) 115
Wilson, M., see Cleland, J.L. (49) 193
Wirth, M., see Gabor, F. (49) 27
Woolfson, A.D., see Jones, D.S. (49) 71
Wu, X.Y., see Zhou, Y. (49) 277
Yang, J., see Cleland, J.L. (49) 193
Yeung, D., see Cleland, J.L. (49) 193
Zhou, Y. and Wu, X.Y., Finite element analysis of diffusional drug release from complex matrix systems. I. Complex geometries and composite structures (49) 277

ELSEVIER

Journal of Controlled Release 49 (1997) 311–312

journal of controlled release

Subject Index Volume 49 (1997)

Albumin release, (49) 253
Artificial membranes, (49) 141
Artificial neural networks, (49) 11
Avoidance of first-pass effect, (49) 105
Bioadhesion, (49) 27
Bioadhesive polyelectrolyte, (49) 167
Bioavailability, (49) 149
Biodegradable polymer, (49) 207
Biodegradation, (49) 157
Bioerodible hydrogel, (49) 253
Biomembranes, (49) 97
Block copolymer, (49) 229
Blood–brain barrier, (49) 81
Brain delivery, (49) 81
Buccal absorption, (49) 105
Caco-2, (49) 27, (49) 39
Captopril, (49) 243
Catalysts, (49) 263
Cathepsin B, (49) 123
Cationic end group, (49) 229
Colon targeting, (49) 115
Complex matrix devices, (49) 277
Composite structures, (49) 277
Controlled drug release, (49) 123
Controlled release, (49) 21
Correlation, (49) 149
Cotransport, (49) 141
Crystallinity, (49) 207
Cytotoxicity, (49) 59
DNA, (49) 59
Dalargin, (49) 81
Dicalcium phosphate, (49) 243
Diclofenac sodium, (49) 149
Diffusion-controlled release, (49) 71, (49) 207
Diffusional drug release, (49) 277
Diffusion, (49) 133
Dissolution, (49) 149
Droplet sizes, (49) 51
Drug conjugate, (49) 123
Effusion, (49) 97
Encapsulation, (49) 133
Enkephalin, (49) 81
Ether functions, (49) 263
Ethylcellulose, (49) 243
Fibrillar collagen, (49) 291
Finite element method, (49) 277
Finite volume, (49) 277
β-galactosidase, (49) 59
Gingival administration, (49) 105
Granulated excipients, (49) 243
HEMA-MMA hydrogel, (49) 217
HT-29, (49) 27
Hairless rat, (49) 89
Heparin, (49) 291
Human growth hormone, (49) 21, (49) 193
Hydrogel, (49) 167
Hydrophobic modification, (49) 167
Hydrophobicity, (49) 1
N-(2-hydroxypropyl)methacrylamide, (49) 123
IEC-18, (49) 39
In vitro release, (49) 157
In vivo biodegradation, (49) 263
In vivo release, (49) 157
In vivo, (49) 89, (49) 193
Interfacial precipitation, (49) 217
Ion exchange drug delivery, (49) 167
Iontophoresis, (49) 89
Isosorbide dinitrate, (49) 105
Lactose, (49) 243
Lipophilic surfactants, (49) 51
Liposome, (49) 177
Mathematical model, (49) 141
Matrix tablet, (49) 149, (49) 243
Mesalazine, (49) 115
Methotrexate, (49) 123
Metronidazole, (49) 71
Microcapsule, (49) 217
Microspheres, (49) 1
Molecular weights, (49) 263
Mucoadhesion, (49) 71
Multi-objective simultaneous optimization, (49) 11
Nanoparticles, (49) 81
Nasal delivery, (49) 185
Nasal enhancers, (49) 185
Naso–lacrimal duct, (49) 185
Nicotine, (49) 177
Nitroglycerin, (49) 105
Non-invasive methodologies, (49) 89

Ocular delivery, (49) 185
Papaverine, (49) 207
Paracellular transport, (49) 39
Parenteral delivery, (49) 21
Penetration enhancer, (49) 229
Penetration, (49) 141
Peptide, (49) 133
Periodontal disease, (49) 71
Permeability, (49) 97, (49) 217
Pharmacoscintigraphy, (49) 115
Phase-inversion membrane, (49) 217
PLGA microspheres, DL-PLGA, (49) 133, (49) 193
Pluronic: PAA complexes, (49) 51
Poloxamers, (49) 21
Poly (L-lactic acid), (49) 207
Poly(2-(dimethylamino)ethyl methacrylate), (49) 59
Poly(ethylene carbonate), (49) 263
Poly(ethylene glycol) macromer, (49) 253
Poly(ethylene glycol), (49) 229
Poly(lactic-co-glycolic acid) microspheres, (49) 157
Polydimethylsiloxane, (49) 229
Polyethylene glycol, (49) 97
Polyhydroxybutyrate, (49) 1
Polylactide, (49) 1
Polysorbate, (49) 81
Pore size, (49) 97
Proliposome, (49) 177
"Proof of concept", (49) 115
Propylene glycol, (49) 141
Rat study, (49) 21
Release rates, (49) 51
Response surface method, (49) 11
Second-order polynomial equation, (49) 11
Semi-interpenetrating polymer networks, (49) 253
Skin tolerance, (49) 89
Solanum tuberosum lectin, (49) 27
Slow disintegrating tablet, (49) 105
Stabilization, (49) 291
Surfactants, (49) 81
Sustained release, (49) 177
Sustained-release tablet, (49) 11
Sustained-release, (49) 51, (49) 105
Synthesis, (49) 263
Taxol, (49) 157
Texture profile analysis, (49) 71
Tight junction, (49) 39
Transdermal delivery, (49) 177
Transdermal penetration, (49) 229
Transfection, (49) 59
Transforming growth factor beta 2 (TGFβ-2), (49) 291
Tritosomes, (49) 123
Vaccines, (49) 1
Wheat germ agglutinin, (49) 27